Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions

Edwards Lifesciences Corp

Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.
TAVR sales $1.0B, growth 5% (6% CC); FY2024 TAVR guidance lowered to 5-7% from 8-10%.
TMTT sales $83M, +75%; FY2024 TMTT guidance raised to high end of $320-340M range.
Entered agreement to acquire JenaValve (aortic regurgitation) and exercised option to acquire Endotronix (PA pressure sensor); total upfront ~$1.2B cash plus up to $445M milestones.
Critical Care sale ($4.2B) on track to close late Q3 2024; Q3 sales guidance $1.56-1.64B, EPS $0.67-0.71.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.